Multishell semiconductor nanocrystals have been synthesized that display intrinsic dual emission with robust photo and thermal stability and attractive thermal sensitivity. Dual emission is ...demonstrated following phase transfer into aqueous media. These nanocrystals are suitable for diverse optical thermometric or thermographic applications in biotechnology or other areas.
Nanocrystal Diffusion Doping Vlaskin, Vladimir A; Barrows, Charles J; Erickson, Christian S ...
Journal of the American Chemical Society,
09/2013, Letnik:
135, Številka:
38
Journal Article
Recenzirano
A diffusion-based synthesis of doped colloidal semiconductor nanocrystals is demonstrated. This approach involves thermodynamically controlled addition of both impurity cations and host anions to ...preformed seed nanocrystals under equilibrium conditions, rather than kinetically controlled doping during growth. This chemistry allows thermodynamic crystal compositions to be prepared without sacrificing other kinetically trapped properties such as shape, size, or crystallographic phase. This doping chemistry thus shares some similarities with cation-exchange reactions, but proceeds without the loss of host cations and excels at the introduction of relatively unreactive impurity ions that have not been previously accessible using cation exchange. Specifically, we demonstrate the preparation of Cd1–x Mn x Se (0 ≤ x ≤ ∼0.2) nanocrystals with narrow size distribution, unprecedentedly high Mn2+ content, and very large magneto-optical effects by diffusion of Mn2+ into seed CdSe nanocrystals grown by hot injection. Controlling the solution and lattice chemical potentials of Cd2+ and Mn2+ allows Mn2+ diffusion into the internal volumes of the CdSe nanocrystals with negligible Ostwald ripening, while retaining the crystallographic phase (wurtzite or zinc blende), shape anisotropy, and ensemble size uniformity of the seed nanocrystals. Experimental results for diffusion doping of other nanocrystals with other cations are also presented that indicate this method may be generalized, providing access to a variety of new doped semiconductor nanostructures not previously attainable by kinetic routes or cation exchange.
Colloidal manganese-doped semiconductor nanocrystals have been developed that show pronounced intrinsic high-temperature dual emission. Photoexcitation of these nanocrystals gives rise to strongly ...temperature dependent luminescence involving two distinct but interconnected emissive excited states of the same doped nanocrystals. The ratio of the two intensities is independent of nonradiative effects. The temperature window over which pronounced dual emission is observed can be tuned by changing the nanocrystal energy gap during growth. This unique combination of properties makes this new class of intrinsic dual emitters attractive for ratiometric optical thermometry applications.
We present an experimental study of the magneto-optical activity of multiple excited excitonic states of manganese-doped CdSe quantum dots chemically prepared by the diffusion doping method. Giant ...excitonic Zeeman splittings of each of these excited states can be extracted for a series of quantum dot sizes and are found to depend on the radial quantum number of the hole envelope function involved in each transition. As seven out of eight transitions involve the same electron energy state, 1Se, the dominant hole character of each excitonic transition can be identified, making use of the fact that the g-factor of the pure heavy-hole component has a different sign compared to pure light hole or split-off components. Because the magnetic exchange interactions are sensitive to hole state mixing, the giant Zeeman splittings reported here provide clear experimental evidence of quantum-size-induced mixing among valence-band states in nanocrystals.
Dopant−carrier magnetic exchange interactions in semiconductor nanostructures give rise to unusually large Zeeman splittings of the semiconductor band levels, raising possibilities for spin-based ...electronics or photonics applications. Here we evaluate the recently highlighted possibility of confinement-induced kinetic s−d exchange coupling in doped ZnSe/CdSe inverted core/shell nanocrystals. Magneto-optical studies of a broad series of Co2+- and Mn2+-doped core, inverted core/shell, and isocrystalline core/shell nanocrystals reveal that the dominant spectroscopic effects caused by CdSe shell growth around doped ZnSe core nanocrystals arise from hole spatial relaxation, being essentially independent of the electron−dopant interaction or the heterointerface itself. The general criteria for observation of kinetic s−d exchange coupling in doped nanocrystals are discussed in light of these results.
Electronic absorption spectroscopy has been used to study changes in Co2+ ligand-field parameters as a function of alloy composition in Co2+-doped Cd(1-x)Zn(x)Se nanocrystals. A shift in the energy ...of the 4T1(P) excited-state with alloy composition is observed. Analysis reveals that Co2+-Se2- bond lengths change relatively little as the host is varied continuously from CdSe to ZnSe, generating a large difference between microscopic and average cation-anion bond lengths in Co2+-doped CdSe nanocrystals but not in Co2+-doped ZnSe nanocrystals. The bimodal bond-length distributions observed here are shown to cause a diameter-dependent enthalpic destabilization of doped semiconductor nanocrystals.
Clinical studies have validated that antiretroviral (ARV) drugs can serve as an HIV pre-exposure prophylactic (PrEP) strategy. Dosing adherence remains a crucial factor determining the final efficacy ...outcomes, and both long-acting implants and injectable depot systems are being developed to improve patient adherence. Here, we describe an injectable depot platform that exploits a new mechanism for both formation and controlled release. The depot is a polymeric prodrug synthesized from monomers that incorporate an ARV drug tenofovir alafenamide (TAF) with degradable linkers that can be designed to control release rates. The prodrug monomers are synthetically incorporated into homopolymer or block designs that exhibit high drug weight percent (wt%) and also are hydrophobized in these prodrug segments to drive depot formation upon injection. Drug release converts those monomers to more hydrophilic pendant groups via linker cleavage, and as this drug release proceeds, the polymer chains losing hydrophobicity are then disassociated from the depot and released over time to provide a depot dissolution mechanism. We show that long-acting TAF depots can be designed as block copolymers or as homopolymers. They can also be designed with different linkers, for example with faster or slower degrading p-hydroxybenzyloxycarbonyl (Benzyl) and ethyloxycarbonyl (Alkyl) linkers, respectively. Diblock designs of p(glycerol monomethacrylate)-b-p(Alkyl-TAF-methacrylate) and p(glycerol monomethacrylate)-b-p(Benzyl-TAF-methacrylate) were first characterized in a mouse subcutaneous injection model. The alkylcarbamate linker design (TAF 51 wt%) showed excellent sustained release profiles of the key metabolite tenofovir (TFV) in skin and plasma over a 50-day period. Next, the homopolymer design with a high TAF drug wt% of 73% was characterized in the same model. The homopolymer depots with p(Alkyl-TAFMA) exhibited sustained TFV and TAF release profiles in skin and blood over 60 days, and TFV-DP concentrations in peripheral blood mononuclear cells (PBMC) were found to be at least 10-fold higher than the clinically suggested minimally EC90 protective concentration of 24 fmol/106 cells. These are the first reports of sustained parent TAF dosing observed in mouse and TFV-DP in mouse PBMC. IVIS imaging of rhodamine labeled homopolymer depots showed that degradation and release of the depot coincided with the sustained TAF release. Finally, these polymers showed excellent stability in accelerated stability studies over a six-month time period, and exceptional solubility of over 700 mg/mL in the DMSO formulation solvent. The homopolymer designs have a drug reservoir potential of well over a year at mg/day dosing and may not require cold chain storage for global health and developed world long-acting drug delivery applications.
Display omitted
Primaquine and tafenoquine are the two 8-aminoquinoline (8-AQ) antimalarial drugs approved for malarial radical cure - the elimination of liver stage hypnozoites after infection with Plasmodium ...vivax. A single oral dose of tafenoquine leads to high efficacy against intra-hepatocyte hypnozoites after efficient first pass liver uptake and metabolism. Unfortunately, both drugs cause hemolytic anemia in G6PD-deficient humans. This toxicity prevents their mass administration without G6PD testing given the approximately 400 million G6PD deficient people across malarial endemic regions of the world. We hypothesized that liver-targeted delivery of 8-AQ prodrugs could maximize liver exposure and minimize erythrocyte exposure to increase their therapeutic window. Primaquine and tafenoquine were first synthesized as prodrug vinyl monomers with self-immolative hydrolytic linkers or cathepsin-cleavable valine-citrulline peptide linkers. RAFT polymerization was exploited to copolymerize these prodrug monomers with hepatocyte-targeting GalNAc monomers. Pharmacokinetic studies of released drugs after intravenous administration showed that the liver-to-plasma AUC ratios could be significantly improved, compared to parent drug administered orally. Single doses of the liver-targeted, enzyme-cleavable tafenoquine polymer were found to be as efficacious as an equivalent dose of the oral parent drug in the P. berghei causal prophylaxis model. They also elicited significantly milder hemotoxicity in the humanized NOD/SCID mouse model engrafted with red blood cells from G6PD deficient donors. The clinical application is envisioned as a single subcutaneous administration, and the lead tafenoquine polymer also showed excellent bioavailability and liver-to-blood ratios exceeding the IV administered polymer. The liver-targeted tafenoquine polymers warrant further development as a single-dose therapeutic via the subcutaneous route with the potential for broader patient administration without a requirement for G6PD diagnosis.
Display omitted
